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OBJECTIVES We sought to study the effect of long-term statin use on psychometric measures in an adult
population with underlying coronary artery disease (CAD).
BACKGROUND Previous studies have suggested associations between cholesterol lowering and psychological
well-being.
METHODS Study subjects were recruited from an outpatient cardiology clinic. Psychological well-being
was assessed at baseline and annually during follow-up. The exposure of interest was
long-term statin use and the outcomes of interest were depression, anxiety, and hostility. We
estimated the odds ratios (ORs) and 95% confidence intervals (CI) that represented the
strength of association between statin use (vs. no use of any cholesterol-lowering drug) and
the risk of having abnormal depression, anxiety, and hostility scores.
RESULTS Study subjects had an average follow-up of four years and maximum of seven years.
Comparing the 140 patients who had continuous use of statins with the 231 patients who did
not use any cholesterol-lowering drugs, statin use was associated with lower risk of abnormal
depression scores (OR 0.63, 95% CI 0.43 to 0.93), anxiety (OR 0.69, 95% CI 0.47 to 0.99),
and hostility (OR 0.77, 95% CI 0.58 to 0.93) after adjustment for the propensity for statin
use and potential confounders. The beneficial psychological effects of the statins appeared to
be independent of the drugs’ cholesterol-lowering effects.
CONCLUSIONS Long-term use of statins among patients with CAD appeared to be associated with reduced
risk of anxiety, depression, and hostility. (J Am Coll Cardiol 2003;42:690–7) © 2003 by the
American College of Cardiology Foundation
Data from clinical trials have demonstrated strong beneficial
effects of the hydroxymethylglutaryl co-A reductase inhib-
itors (statins) on both primary and secondary prevention of
coronary artery disease (CAD) (1–5). The benefits of the
statins have even been reported among coronary patients
with average serum cholesterol levels (6–8), suggesting that
statins have benefits beyond their effect on cholesterol. In
addition, the statins appear to exert a wide range of
beneficial effects beyond their effect on CAD, including a
reduction in the risk of dementia (including Alzheimer’s
disease) (9–11), stroke (12), macular degeneration (13), and
osteoporosis (14–16). With such potential benefits, the use
of statins might burgeon well beyond the 36 million (17)
patients recently estimated to be eligible for statin therapy
according to the guidelines of the National Cholesterol
Education Program (NCEP) (18,19). As expanding seg-
ments of the population are exposed to statins for prolonged
periods, it will be important to gain a more complete
understanding of the wide range of effects of statins,
including those direct hepatic (cholesterol-lowering) effects
and indirect or extra-hepatic effects.
Observations of more than a decade ago suggested that
vigorous cholesterol lowering had an adverse impact on
psychological well-being (20–27) that included clinical
depression, violent behavior, and even suicide. The recent
findings of statins’ effects on multiple organ systems have
given rise to a new interest in their potential psychological
effects (28,29). To assess the association between prolonged
statin usage and psychological well-being, we reviewed data
from a long-term study of an outpatient cohort of individ-
uals with underlying CAD.
METHODS
Study population and data collection. Study subjects were
recruited from patients treated at the Lown Cardiovascular
Center, an outpatient cardiology referral clinic affiliated
with the Brigham and Women’s Hospital and Harvard
Medical School. Details of the scientific rationale, design,
eligibility requirements, and baseline characteristics of the
cohort have been published elsewhere (30,31). Consecutive
patients with CAD, seen at this clinic from December 1994
and thereafter, were screened and enrolled in a prospective
study. Patients were not eligible for enrollment in this
longitudinal study if they had undergone prior coronary
revascularization (percutaneous or surgical), had moderate
to advanced congestive heart failure (New York Heart
Association class III or IV), had advanced valvular heart
disease, or had severe or life-limiting non-cardiac illnesses.
Upon study enrollment, after patients provided informed
consent, their sociodemographic, psychological, and clinical
data were collected. Thereafter, patients completed annual
follow-up questionnaires either at the time of a scheduled
clinic visit or by mail. In addition, the cardiologists treating
these patients provided clinical data, including medication
usage, annually during follow-up. Patient follow-up is
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ongoing, and data accrued until June 2001 are included in
this report. Average follow-up time was four years, and the
longest follow-up was seven years.
Exposure and outcome of interest. Information about
medication usage was abstracted from patients’ medical
records and their annual questionnaires. Cholesterol-
lowering drugs were classified as statins (simvastatin, ator-
vastatin, fluvastatin, lovastatin, cerivastatin, and pravastatin)
or non-statin lipid-lowering agents (gemfibrozil, cholestyra-
mine, clofibrate, colestipol, and probucol). Statin usage was
the exposure of interest. Patients were divided into three
mutually exclusive groups according to statin use during the
study period: those who were continuously prescribed sta-
tins (always); those who had prescriptions for statins, but
not continuously, during the entire study period (intermit-
tent); and those who had never used a cholesterol-lowering
drug (never). A fourth group consisting of those who used
only non-statin cholesterol-lowering drugs was included at
the end of the study for comparison, but it was not included
in the primary analysis.
The primary outcomes of interest were anxiety, depres-
sion, and hostility as measured by The Kellner Symptom
Questionnaire (SQ) (32). At study entry and during their
annual physician visits, patients filled out Kellner SQ,
Buss-Durkee (33), Cook-Medley (34), Health Locus of
Control (HLC) (35,36), as well as Schedule of Recent and
Anticipated Experiences (SRE) (37). The Kellner SQ
consists of 92 items that yield four scale scores—depression,
anxiety, hostility, somatization—and a total distress score.
In addition to analyzing these scores as continuous variables,
we also classified patients’ scores for anxiety, depression, and
hostility as “normal” or “abnormal.” We dichotomized this
continuous outcome because the Kellner scale, like any
other scale, is only quasi-continuous and has artificial lower
and upper boundary. Moreover, the dichotomization re-
duces the influence of outliers. Finally, although the cutoff
points cannot and should not be used to make psychiatric
diagnosis, we wanted to use the categorical changes (normal
vs. abnormal) to capture substantial and qualitative changes
in addition to the numerical changes. A depression score of
seven or above, an anxiety score of eight or above, and a
hostility score of eight or above were labeled as abnormal
(32).
We chose the Kellner scale as our focus because it
measured all three aspects of psychological well-being—
anxiety, depression, and hostility. To confirm the reliability
and validity of the Kellner scale, we ran additional analyses
using Buss-Durkee and Cook-Medley scales. In addition,
past major life events and anticipated major future life
events were measured using the SRE Questionnaire (37).
The HLC scale is an 11-item scale developed to measure
personality traits that are related to medical decisions in
order to predict health-related behavior. Finally, we recog-
nize the importance of social support and its impact on both
psychological well-being and medical decisions, thus we
included a composite variable (Social Support) based on the
Berkman-Syme Social Network Index (38).
Statistical analysis. Comparisons of psychometric scores
were made among the three statin exposure groups (always
use, intermittent use, and no cholesterol-lowering drug use).
Odds ratios (ORs) and accompanying 95% confidence
interval (CI) were calculated to represent the strength of
association between statin exposure and abnormal SQ scores
for anxiety, depression, and hostility. The generalized esti-
mating equations (GEE) method (39) was used to account
for the longitudinal nature of the annually collected data on
the exposure of interest (statin use) and outcomes (SQ
scores), and logistic GEE models were employed to esti-
mate the corresponding ORs and their 95% CIs. We
controlled for baseline characteristics that included age,
gender, education (below vs. above college education), use
of antidepressants and anxiolytic drugs, history of hyperten-
sion, diabetes, myocardial infarction (MI), smoking, regular
exercise, alcohol use, past major life events, personality,
social support, and total cholesterol level at entry. We also
used the GEE model to control for events and changes that
occurred during follow-up: changes in total cholesterol level;
occurrence of MI; stroke; concomitant use of beta-blockers
and calcium channel blockers; cardiac catheterization or
revascularization; and anticipated major future life events.
More importantly, when we tried to evaluate the psycho-
logical effects associated with long-term statin usage, we
decided that total number of years of statin use would be
inadequate, as some patients would discontinue using statin
for a period of time and then resume use of the medication
again. As a result, the number of consecutive years of statin
use was employed in the present study as a proxy measure
for cumulative exposure. Lengths of statin usage were
categorized as number of consecutive years of usage, to
investigate a potential exposure threshold beyond which
reduced abnormal psychometric scoring risk would be ob-
served. The number of consecutive years of statins exposure
was evaluated as an independent variable in separate uni-
variate and multivariate models to evaluate the effects of
cumulative exposure, with person-time that was not exposed
to any cholesterol-lowering drug as the reference group.
We compared not only those who were receiving statin
treatment with those who were not receiving any
cholesterol-lowering drugs, but also we compared psycho-
metric scores in the same patient while receiving versus
while not receiving statin treatment among those patients
who had intermittent usage of statins. As a result, some
subjects served as their own controls as well as controls for
others.
Abbreviations and Acronyms
CAD  coronary artery disease
GEE  generalized estimating equations
MI  myocardial infarction
SQ  (The Kellner) Symptom Questionnaire
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Because statin use was not randomly assigned in this
patient population, potential confounding and selection
biases were accounted for by developing a propensity score
for statin use. Propensity analysis (40) was performed
regarding the probability of statin prescription. For each
patient, a propensity score indicating the likelihood of
having statins prescribed was calculated by multivariate
logistic regression analysis (41). The propensity for statin
use was determined without regard to outcome. A full
non-parsimonious model was developed that included 24
covariates, all of which are listed in Table 1. The multivar-
iate regression model of propensity for statin use had a c
statistic of 0.86, which represents the area under the receiver
operating characteristic curve, indicating a good ability to
differentiate between statin users and nonusers. The score
ranged from 0.03 to 0.97, representing the probability that
a patient would be prescribed statin.
All these variables, together with individual propensity
scores, were forced into the logistic GEE models evaluating
the association of statin use and psychological well-being.
All analyses were carried out using STATA 7.0 (Stata
Corporation, College Station, Texas).
RESULTS
Between December 1992 and June 2001, 2,598 men and
women of all ages with CAD were screened for enrollment
at the Lown Cardiovascular Center; 761 subjects met our
study’s inclusion criteria and agreed to participate. A total of
606 patients who had at least one year of follow-up, baseline
psychometric data, and complete medication information
were included in this analysis. As selective attrition could
potentially bias the results of our study, we paid special
attention to the survey response rate. The response rate for
completing the psychometric questionnaires was consis-
tently high—an average of 91%. During follow-up, only 25
subjects (4%) voluntarily withdrew from the study, and 36
subjects (6%) died.
Baseline characteristics of patients in the always-used
statins, intermittent use of statins, and no cholesterol-
lowering drug use groups were similar, including their
psychometric profile (Table 1). Although those who were
intermittently using statins had slightly higher levels of total
serum cholesterol, their average total cholesterol was not
clinically significant according to the NCEP guidelines.
Patients who were using statins showed a trend toward
better psychometric scores for depression, anxiety, and
hostility as measured by the Kellner scale during follow-up,
while there was little change in these scores among those
who did not use any cholesterol-lowering drugs (Fig. 1).
Additional analyses were performed using other psychomet-
ric scales, and similar results were found (not reported).
Using the logistic GEE model to account for repeated
assessment of statin usage and psychometric scores, we
found that those who used statins continuously throughout
the study period were significantly less likely to have
abnormal depression scores (OR 0.63, 95% CI 0.43 to
0.93), abnormal anxiety scores (OR 0.69, 95% CI 0.47 to
0.99), and abnormal hostility scores (OR 0.77, 95% CI 0.58
to 0.93) (Table 2). The beneficial effects of statin exposure
were found after we adjusted for differences in baseline
characteristics and clinical events during follow-up, the
most important ones being baseline psychometric scores,
baseline and change in cholesterol level, and baseline psy-
chosomatic medication usage. Patients who used statins
intermittently did not show the same beneficial effects
(Table 2).
Employing the number of years of statin use as the
exposure of interest and person-years not using any
cholesterol-lowering drug as reference, the consecutive years
of statin use were associated with a lower risk of having
abnormal depression, anxiety, and hostility scores, after
adjusting for the potential confounders described above
(Fig. 2). After including those who used non-statin
cholesterol-lowering drugs, we found that the observed
beneficial psychological effects were most prominent among
those who used statins in contrast to non-statin cholesterol-
lowering drugs (Table 3).
We investigated whether the association between statin
use and abnormal psychometric scores depended on baseline
serum cholesterol levels and on changes in these levels
during follow-up. We examined the risk of developing
abnormal psychometric scores according to statin use in
Table 1. Baseline Characteristics of Study Subjects According to
Statin Usage
Statin Usage* Always Intermittent Never
Number of subjects 140 219 231
Age at entry (mean, yrs) 64 66 70
Male (%) 79 83 81
College and above education (%) 65 70 59
Mean blood glucose (mean, mg/dl) 114 117 117
Blood pressure (mean, mm Hg) systolic 134 136 137
Blood pressure (mean, mm Hg) diastolic 77 78 77
Total cholesterol (mean, mg/dl) 206 208 201
HDL cholesterol (mean, mg/dl) 41 38 41
History of smoking (%) 66 68 65
Current smokers (%) 8 5 6
Regular exercise (%) 87 88 82
Beta blockers (%) 71 71 68
ACE inhibitor (%) 10 12 7
Calcium channel blockers (%) 61 52 55
Aspirin (%) 84 81 75
History of catheterization (%) 35 40 31
History of myocardial infarction (%) 41 40 45
History of hypertension (%) 51 57 55
History of diabetes (%) 17 17 12
Depression (SQ) (mean) 6 6 6
Anxiety (SQ) (mean) 7 7 7
Hostility (SQ) (mean) 8 8 8
Health locus of control (mean) 39 40 39
Social support (mean) 4 4 4
*The “Always” group includes those who were on statins throughout the study. The
“Intermittent” group includes those who were on statins intermittently throughout the
study. The “Never” group includes those who were never on any cholesterol-lowering
drugs throughout the study.
ACE  angiotension-converting enzyme; HDL  high-density lipoprotein;
SQ  (Kellner) Symptom Questionnaire.
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patients with baseline normal (200 mg/dl), intermediate
(200–239 mg/dl), and elevated (240 mg/dl) total serum
cholesterol levels (Table 4). Furthermore, the study sample
was divided into four groups of relatively equal sizes
according to the percentage change in total serum choles-
terol levels between the time of enrollment and termination
of follow-up. Within each of the groups of total cholesterol,
and each of the groups of change in total cholesterol, relative
risks consistently indicated a reduced likelihood of develop-
ing abnormal psychometric scores (Table 4). In a multivar-
iate logistic GEE model, entering cholesterol level and
percentage change in cholesterol level separately and then
together, we found that the inclusion of these variables did
not alter the association between statin use and abnormal
psychometric scores.
DISCUSSION
The results of this observational study suggest that long-
term statin therapy consistently improves psychological
well-being among a cohort of patients with CAD. A
progressive, cumulative reduction in the levels of depression,
anxiety, and hostility was observed over a prolonged period
of statin use. This finding was the outcome of a longitudi-
nal, multivariate analysis that controlled for many potential
confounding effects and the propensity for statin prescrip-
tion. The possible impact on psychometric scores was
independent of the serum cholesterol level at baseline and of
the degree of reduction in cholesterol level during follow-
up.
Several earlier studies (29,42,43) have demonstrated no
Figure 1. Association between change in Kellner Symptom Questionnaire score and consecutive years of statin use or no use of cholesterol-lowering
drugs.
Table 2. Association of Abnormal Scoring With Statin Usage
by Psychometric Scales
Statin Use Depression Anxiety Hostility
Adjusted with
propensity*
Always 0.63 (0.43–0.93) 0.69 (0.47–0.99) 0.77 (0.58–0.93)
Intermittent 0.81 (0.59–1.10) 0.96 (0.71–1.31) 0.94 (0.75–1.19)
Never referent referent referent
Adjusted†
Always 0.64 (0.43–0.93) 0.62 (0.43–0.90) 0.65 (0.45–0.93)
Intermittent 0.80 (0.59–1.11) 0.92 (0.68–1.24) 0.94 (0.71–1.26)
Never referent referent referent
Crude
Always 0.66 (0.50–0.86) 0.67 (0.51–0.87) 0.79 (0.62–1.02)
Intermittent 0.86 (0.69–1.06) 0.96 (0.78–1.19) 0.98 (0.80–1.20)
Never referent referent referent
*GEE longitudinal multivariate model with adjustment for propensity as well as age
(age  mean age); length of follow-up; gender; education (below vs. above college
education); blood glucose level; systolic, diastolic blood pressure; total cholesterol;
high-density lipoprotein, heart rate; current smoking; regular exercise; alcohol use;
past major life events; anticipated major future life events; use of antidepressants and
anti-anxiety drugs at time of enrollment; statin usage prior to study entry; use of
beta-blockers, calcium channel blockers at enrollment and during follow-up; history
of catheterization, myocardial infarction, hypertension, diabetes; incidence of myo-
cardial infarction, stroke, catherization, revascularization. †Same as above, but not
including propensity score.
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association between statins and psychological state. Al-
though our findings agree with the results that statins
produce no harmful psychological effects, these studies are
methodologically different from ours in several important
aspects: their study populations were different from ours;
their choice of medication was too limited—for example,
only hydrophilic statin; and all of their follow-up periods
were shorter. We observed changes in the psychometrics
Figure 2. Odds ratios of abnormal psychometric scores and length of consecutive statin usage. *The generalized estimating equations longitudinal
multivariate model with adjustment for propensity, as well as age (age minus mean age); length of follow-up; gender; education (below vs. above college
education); blood glucose level; systolic and diastolic blood pressure; total cholesterol; high density lipoprotein level; heart rate; current smoking; regular
exercise; alcohol use; past major life events; anticipated major future life events; use of antidepressants and anti-anxiety drugs at time of enrollment; statin
use prior to study entry; use of beta blockers or calcium channel blockers at enrollment and during follow-up; history of catheterization, myocardial
infarction, hypertension, and diabetes; incidence of myocardial infarction, stroke, catheterization, and revascularization.
Table 3. Association Between Abnormal Scoring With Cholesterol-Lowering Treatment by
Types of Cholesterol-Lowering Drugs
Person Year Depression Anxiety Hostility
Adjusted*
All 1,001 0.77 (0.63–0.97) 0.77 (0.62–0.96) 0.79 (0.64–0.98)
Non-statin 133 0.85 (0.33–2.18) 0.81 (0.39–1.85) 0.83 (0.38–1.90)
Statins 868 0.77 (0.61–0.96) 0.75 (0.58–0.97) 0.78 (0.63–0.98)
Hydrophilic 148 0.89 (0.50–1.59) 1.06 (0.64–1.77) 0.87 (0.44–1.35)
Lipophilic 720 0.75 (0.60–0.96) 0.75 (0.59–0.95) 0.78 (0.62–0.98)
Crude
All 1,001 0.78 (0.65–0.96) 0.74 (0.60–0.91) 0.74 (0.61–0.89)
Non-statin 133 0.92 (0.31–1.66) 0.92 (0.46–1.86) 1.12 (0.53–2.34)
Statins 868 0.78 (0.64–0.96) 0.73 (0.58–0.92) 0.73 (0.58–0.88)
Hydrophilic 148 0.92 (0.55–1.52) 0.98 (0.61–1.57) 0.86 (0.52–1.42)
Lipophilic 720 0.77 (0.63–0.95) 0.72 (0.58–0.89) 0.72 (0.59–0.88)
Data are presented as odds ratio (95% confidence interval). *Generalized estimating equations longitudinal multivariate model
with adjustment for age (age  mean age); length of follow-up; gender; education (below vs. above college education); blood
glucose level; systolic, diastolic blood pressure; total cholesterol; high-density lipoprotein; heart rate; current smoking; regular
exercise; alcohol use; past major life events; anticipated major future life events; use of antidepressants and anti-anxiety drugs at
time of enrollment; lipid-lowering agent usage prior to study entry; use of beta-blockers, calcium channel blockers at enrollment
and during follow-up; history of catheterization, myocardial infarction, hypertension, diabetes; incidence of myocardial
infarction, stroke, catheterization, revascularization.
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only after a full year of statin treatment. It is possible that a
longer period of exposure to statins is required to generate
an observable impact (Fig. 1).
A number of methodological issues need to be considered
when interpreting our findings. The Kellner questionnaire is
well validated for detecting change in depression, anxiety,
and hostility over time (32). Nevertheless, complex social
constructs, such as psychological well-being, have no uni-
versally agreed upon definition or measure, and the cutoff
points used to define abnormal depression, anxiety, and
hostility may not be sufficient to determine completely the
psychological state of an individual (32). The Kellner SQ
has been shown in both cohort studies and clinical trials to
discriminate the effects of different medical treatments.
Based on longitudinal studies of psychiatric patients,
changes in score were found to correspond with the changes
in rating made by psychiatrists using standard psychiatric
rating scales (32). To ensure the validity of the Kellner scale
in our study, we performed additional analyses, including
the Buss-Durkee and Cook-Medley scales, and found
similar results (not shown).
Study limitations. A prospective cohort study is subject to
loss of study subjects due to follow-up. In this study, the
more depressed, more anxious, or more hostile subjects
might be more likely to drop out of the study or not fill out
their questionnaires. However, it is highly unlikely that the
loss to follow-up occurred preferentially among regular
statin users, and our very high response rate is not likely to
generate substantial information bias. The possibility that
physicians withhold statins from those patients who are
more depressed or anxious is very doubtful, as statins were
prescribed based purely on cardiovascular conditions.
Compliance with the prescription of statins as well as
other cardiac drugs has been studied (44). It was found that
lipid-lowering drugs in general had a higher rate of com-
pliance (88%) than other cardiac medicines. Moreover,
noncompliance would lead to misclassification, which
would bias the results towards the null and therefore tend to
underestimate the association.
Although statins have become the standard treatment for
hypercholesterolemia over the past decade, they did not
achieve their current status until the latter half of the 1990s.
Our study began in 1992, at a time when prescribing a statin
was not as routine as it has become. Instead of medicine,
patients were often placed on an exercise and/or a diet
program. Our data suggest that the proportion of patients
being prescribed statins indeed has been steadily on the rise
without significant change in the clinical characteristics of
the patients. Moreover, statins increasingly were prescribed
for preventive purposes in patients with normal baseline
serum cholesterol levels. Because of the steadily declining
threshold for statin treatment, some patient who were not
initially receiving statins began statin therapy during the
study. Nevertheless, some patients stopped taking statins
because of side effects and tried other medication and/or
diet/exercise programs. These were the main reasons for
intermittent use of statins.
We performed propensity analyses to minimize con-
founding. A propensity score was included in all multivar-
iate logistic GEE models to reduce confounding by factors
associated with statin treatment as well as with improved
psychological well-being. Using this approach, we found
that the main results were similar in all subgroup analyses
(Table 2), suggesting that the observed improvement in
psychological well-being was related to statin treatment
rather than patient selection.
We controlled for many potential confounders, except for
non-cardiovascular co-morbidity. Patients with severe or
life-limiting noncardiac illnesses were excluded from study
entry. Although co-morbidities can be independent risk
factors for depression, anxiety, and hostility, they are un-
likely to be associated with an exposure to the statins—
unless related to hepatic impairment. Concomitant medi-
cations, particularly those drugs that affect the central
nervous system or other drugs that may have a psychological
impact, may be associated with psychological well-being,
but we found no association between prescriptions for
Table 4. Risk of Abnormal Psychometric Score by Cholesterol
and Changes in Cholesterol
Depression
Total cholesterol at baseline (no.)* OR (95% CI) p Value
Cholesterol 200 (255, 59% on statins) 0.73 (0.52–1.02) 0.07
Cholesterol 200–239 (205, 62% on statins) 0.72 (0.49–1.03) 0.06
Cholesterol 240 (130, 63% on statins) 0.64 (0.39–1.04) 0.07
% Drop in total cholesterol level (no.)†
30% (223) 0.59 (0.40–0.89) 0.01
30% to 21% (135) 0.62 (0.31–1.23) 0.17
20% to 11% (138) 0.51 (0.27–0.95) 0.04
10% or less (94) 0.61 (0.43–0.85) 0.01
Anxiety
Total cholesterol at baseline (no.)* OR (95% CI) p Value
Cholesterol 200 (255, 59% on statins) 0.69 (0.50–0.95) 0.02
Cholesterol 200–239 (205, 62% on statins) 0.68 (0.50–0.94) 0.02
Cholesterol 240 (130, 63% on statins) 0.71 (0.39–1.31) 0.28
% Drop in total cholesterol level (no.)†
30% (223) 0.60 (0.39–0.92) 0.02
30% to 21% (135) 0.74 (0.49–1.12) 0.15
20% to 11% (138) 0.68 (0.46–0.99) 0.05
10% or less (94) 0.90 (0.59–1.37) 0.63
Hostility
Total cholesterol at baseline (no.)* OR (95% CI) p Value
Cholesterol 200 (255, 59% on statins) 0.73 (0.55–0.96) 0.03
Cholesterol 200–239 (205, 62% on statins) 0.69 (0.50–0.96) 0.03
Cholesterol 240 (130, 63% on statins) 0.84 (0.55–1.29) 0.43
% Drop in total cholesterol level (no.)†
30% (223) 0.73 (0.48–1.10) 0.13
30% to 21% (135) 0.72 (0.47–1.09) 0.12
20% to 11% (138) 0.73 (0.50–1.05) 0.09
10% or less (94) 0.85 (0.59–1.23) 0.39
*Serum cholesterol level at entry was grouped by clinically relevant cutoff points. The
numbers in parentheses are the number of study subjects in each category. †Changes
in cholesterol level were measured by taking the difference between the cholesterol
level at entry and at the end of follow-up for each patient.
CI  confidence interval; OR  odds ratio.
695JACC Vol. 42, No. 4, 2003 Young-Xu et al.
August 20, 2003:690–7 Long-Term Statin Use and Psychological Well-Being
antidepressants, anxiolytics, beta-adrenergic blocking
agents, calcium-channel blocking agents, and prescriptions
for statins. There was no material change in the findings
after we controlled for baseline usage of antidepressants
and/or anxiolytic drugs. Any unmeasured confounders that
would generate a spurious association would have to be a
strong predictor of psychological outcomes and affect the
choice of statins over no treatment. However, the treatment
decision was based solely on a patient’s cardiovascular
disease risk profile, and the prospectively assessed variables
have already been controlled for in the statistical model.
This study has several strengths in comparison to previ-
ous studies. The cohort was relatively large and spans the
longest follow-up time reported to date. The study also
included all the statins rather than just one at a time, as in
previous studies. We took into account significant social,
medical, and financial life events. Furthermore, we adjusted
for cardiac events (MI, stroke, coronary catheterization, and
revascularization), exercise, education, smoking, and alcohol
consumption, in addition to medication, cholesterol profile,
and clinical characteristics.
Our observational study aims to generate further hypoth-
eses and interest in the psychological impact of the statin
drugs and in no way should influence how statins are
prescribed. The lipophilic statins, as opposed to all other
cholesterol-lowering drugs, appear primarily responsible for
the observed effect on psychological well-being. Because of
the small number of patients treated only with hydrophilic
statins or non-statin cholesterol-lowering drugs, we cannot
rule out the role of chance, but we hypothesize that the
penetration of the blood-brain-barrier by the lipophilic
statins accounts for most of the observed impact on psycho-
logical well-being. This hypothesis requires further testing.
Conclusions. Psychometric instruments administered an-
nually for up to seven years revealed a progressive reduction
in levels of depression, anxiety, and hostility in CAD
patients continuously treated with statins. This effect ap-
pears to be independent of the impact of statin use on serum
cholesterol level.
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